General Psychiatry - Articles - Page 2

When Care Crosses the Line: Petra’s Story

October 1, 2025

Daniel Carlat, MD

For LGBTQIA+ older adults, that line is crossed more often than we think.

Sometimes it looks like concern.

Sometimes it’s framed as protection.

But the impact is the same: autonomy is eroded, piece by piece.

Learning Objectives, Patient Education, TCPR, October 2025

October 1, 2025

After reading these articles, you should be able to…

Note From the Editor-in-Chief

An App for Tardive Dyskinesia

October 1, 2025

Chris Aiken, MD

Second-generation antipsychotics have cut the risk of tardive dyskinesia (TD) in half—from 7% to 3% per year—but it is still a problem.

Expert Q&A

Dana Dieringer, MD. Assistant Professor, UW Medicine, Department of Psychiatry and Behavioral Sciences, Seattle, WA. Dr. Dieringer has no financial relationships with companies related to this material.

Dr. Dana Dieringer shares practical strategies for navigating some of psychiatry’s toughest conversations.

Research Update

Mania and Corticosteroids: Beyond Bipolar Disorder

October 1, 2025

Sy Clark, MD

Sy Clark, MD. Dr. Clark has no financial relationships with companies related to this material.

Steroid-induced mania doesn’t just happen in bipolar disorder. This review tells us how common it is in the general population and when to expect it.

Research Update

Lithium as Effective as IV Ketamine Augmentation in Treatment-Resistant Depression

October 1, 2025

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

The analysis ranks the efficacy of ketamine, esketamine, lithium, and aripiprazole in TRD.

Research Update

Do Benzodiazepines and z-Hypnotics Lead to Long-Term or High-Dose Use?

October 1, 2025

Jeremy Mills, DNP, PMHNP-BC

Jeremy Mills, DNP, PMHNP-BC. Dr. Mills has no financial relationships with companies related to this material.

Most patients prescribed benzodiazepines or Z-drugs don’t escalate use—but a small group does. This study identifies who’s at risk for long-term use and higher-than-recommended doses.

Research Update